Marina Biotech (MRNA) Reports Q4 Revenues Above Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress
March 6, 2019 7:00 AM ESTShows Continued Execution Across its Pipeline of Infectious Disease, Immuno-Oncology and Rare Disease Programs
Ends Year With $1.7 Billion in Cash, Cash Equivalents and Investments
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the fourth quarter and full year of 2018 and highlighted pipeline progress since the Companys last corporate update in January.
New updates announced today include:... More
